Should I Buy MOLN? MOLN 2026 Analysis

Should You Buy Molecular Partners AG (MOLN) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

4.090

1 Day change

-1.45%

52 Week Range

5.350

Analysis Updated At

2026/01/30

Not a good buy right now. With no Intellectia buy signals, a mildly bearish-to-neutral technical setup, and weak latest-quarter fundamentals (zero revenue and ongoing losses), the risk/reward is not attractive for an impatient buyer despite one very bullish new analyst initiation. I would avoid initiating a position pre-market at ~4.15 and treat it as a hold/watch until a clear momentum signal or concrete pipeline catalyst appears.

Technical Analysis

Price/levels: Pre-market ~4.1501, sitting just above the pivot (4.118). Near-term resistance is close overhead at R1 4.242 then R2 4.318; supports are S1 3.993 then S2 3.917. Momentum: MACD histogram is negative (-0.0048) but contracting, suggesting downside momentum is fading rather than reversing strongly. RSI: RSI_6 ~55.7 (neutral), not oversold—so there’s no strong mean-reversion “cheap” signal. Trend: Moving averages are converging, consistent with consolidation/range conditions rather than a confirmed uptrend. Pattern-based probability: Similar-pattern model implies a modest negative drift (60% chance of ~-0.96% next day, ~-4.04% next month). **Intellectia Proprietary Trading Signals** - [AI Stock Picker](module://ai_stock_pick): no signal on given stock today. - [SwingMax](module://swingmax): No signal on given stock recently.

Options Data

Positive Catalysts

with a Buy and a $13 price target, highlighting the DARPin platform and targeted radiotherapy focus—could improve sentiment/visibility. MACD downside momentum is contracting, which can precede stabilization if buyers step in near support.

Neutral/Negative Catalysts

and continuing losses, which can cap upside absent a clear catalyst. Technical setup is not in a confirmed uptrend (neutral RSI, negative MACD, converging MAs) and pattern-based outlook skews slightly negative. Broader tape is risk-off pre-market (S&P 500 -0.8%), which can pressure small-cap/biotech names.

Financial Performance

2025/Q3: Revenue dropped to 0 (-100% YoY). Net income was -11.836M (down -27.85% YoY). EPS was -0.33 (down -32.65% YoY). Gross margin dropped to 0 (-100% YoY). Overall, the quarter reflects no current revenue base and widening per-share losses versus last year—growth trend is weak and relies on pipeline progress rather than operating momentum.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend: JPMorgan (2025-12-08) maintained Neutral and lowered price targets (~$4 to $3.75 / CHF 3.50 to CHF 3), signaling limited near-term conviction. More recently, H.C. Wainwright (2026-01-27) initiated with Buy and a $13 target—sharp positive shift from a smaller shop. Wall Street pros: Potential upside if DARPin/targeted radiotherapy programs deliver meaningful pipeline readouts; bullish initiation can attract speculative interest. Wall Street cons: Larger-bank stance remains neutral with reduced targets, implying skepticism about near-term catalysts/visibility. Ownership/politicians: No recent congress trading data available; hedge funds and insiders show no significant recent trend (neutral).

2 Analyst Rating

Wall Street analysts forecast MOLN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MOLN is 10 USD with a low forecast of 8 USD and a high forecast of 12 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 4.150

Low

Averages

High

Current: 4.150

Low

Averages

High

H.C. Wainwright

Buy

initiated

$13

AI Analysis

2026-01-27

New

Reason

H.C. Wainwright

Price Target

$13

AI Analysis

2026-01-27

New

initiated

Buy

Reason

H.C. Wainwright initiated coverage of Molecular Partners with a Buy rating and $13 price target. The company is advancing a "diversified portfolio of agents" centered on the DARPin platform, the analyst tells investors in a research note. The firm says Molecular Partners is focused on targeted radiotherapy agents to address areas of serious unmet needs within oncology.

JPMorgan

Richard Vosser

Neutral

downgrade

2025-12-08

Reason

JPMorgan

Richard Vosser

Price Target

2025-12-08

downgrade

Neutral

Reason

JPMorgan analyst Richard Vosser lowered the firm's price target on Molecular Partners to $3.75 from $4 and keeps a Neutral rating on the shares. The firm adjusted ratings and targets in the European pharma group as part of its 2026 outlook. It expects sector performance to be driven by pipeline readouts, saying much of the concern around the impact of U.S. price pressure on sector earnings has dissipated in Q4. JPMorgan downgraded companies with a lack of pipeline readouts in 2026.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for MOLN

Unlock Now

MOLN Should I Buy

MOLN Should I Buy

Should You Buy Molecular Partners AG (MOLN) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch